Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers.

Bird AK, Chang M, Barnard J, Goldman BI, Meednu N, Rangel-Moreno J, Anolik JH.

J Immunol. 2017 Jul 15;199(2):458-466. doi: 10.4049/jimmunol.1700354. Epub 2017 Jun 5.

PMID:
28584005
2.

Inhibition of G Protein βγ Subunit Signaling Abrogates Nephritis in Lupus-Prone Mice.

Rangel-Moreno J, To JY, Owen T, Goldman BI, Smrcka AV, Anolik JH.

Arthritis Rheumatol. 2016 Sep;68(9):2244-56. doi: 10.1002/art.39673.

3.

Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis.

Meednu N, Zhang H, Owen T, Sun W, Wang V, Cistrone C, Rangel-Moreno J, Xing L, Anolik JH.

Arthritis Rheumatol. 2016 Apr;68(4):805-16. doi: 10.1002/art.39489.

4.

New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome.

Bird AK, Meednu N, Anolik JH.

Curr Opin Rheumatol. 2015 Sep;27(5):461-7. doi: 10.1097/BOR.0000000000000201. Review.

5.

Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.

Adlowitz DG, Barnard J, Biear JN, Cistrone C, Owen T, Wang W, Palanichamy A, Ezealah E, Campbell D, Wei C, Looney RJ, Sanz I, Anolik JH.

PLoS One. 2015 Jun 5;10(6):e0128269. doi: 10.1371/journal.pone.0128269. eCollection 2015.

6.

NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB.

Zhang H, Hilton MJ, Anolik JH, Welle SL, Zhao C, Yao Z, Li X, Wang Z, Boyce BF, Xing L.

J Clin Invest. 2014 Jul;124(7):3200-14. doi: 10.1172/JCI68901. Epub 2014 Jun 2.

7.

Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.

Wang W, Rangel-Moreno J, Owen T, Barnard J, Nevarez S, Ichikawa HT, Anolik JH.

J Immunol. 2014 Apr 1;192(7):3011-20. doi: 10.4049/jimmunol.1302003. Epub 2014 Feb 26.

8.

Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus.

Palanichamy A, Bauer JW, Yalavarthi S, Meednu N, Barnard J, Owen T, Cistrone C, Bird A, Rabinovich A, Nevarez S, Knight JS, Dedrick R, Rosenberg A, Wei C, Rangel-Moreno J, Liesveld J, Sanz I, Baechler E, Kaplan MJ, Anolik JH.

J Immunol. 2014 Feb 1;192(3):906-18. doi: 10.4049/jimmunol.1302112. Epub 2013 Dec 30.

9.

B cell biology: implications for treatment of systemic lupus erythematosus.

Anolik JH.

Lupus. 2013 Apr;22(4):342-9. doi: 10.1177/0961203312471576. Review.

PMID:
23553777
10.

Treatment targets in systemic lupus erythematosus: biology and clinical perspective.

Marian V, Anolik JH.

Arthritis Res Ther. 2012;14 Suppl 4:S3. doi: 10.1186/ar3917. Epub 2012 Nov 30. Review.

11.

Quantitative proteomics of parotid saliva in primary Sjögren's syndrome.

Ambatipudi KS, Swatkoski S, Moresco JJ, Tu PG, Coca A, Anolik JH, Gucek M, Sanz I, Yates JR 3rd, Melvin JE.

Proteomics. 2012 Oct;12(19-20):3113-20. doi: 10.1002/pmic.201200208. Epub 2012 Sep 10.

12.

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.

Arthritis Res Ther. 2011;13(6):R209. doi: 10.1186/ar3542. Epub 2011 Dec 16.

13.

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH.

Arthritis Rheum. 2012 Feb;64(2):493-503. doi: 10.1002/art.33333. Erratum in: Arthritis Rheum. 2012 Mar;64(3):939.

14.

B cell immunology for the clinician.

Marcus C, Dhillon G, Anolik JH.

Pediatr Infect Dis J. 2011 Feb;30(2):158-60. doi: 10.1097/INF.0b013e318207447f. Review. No abstract available.

15.

Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH.

Arthritis Rheum. 2010 Aug;62(8):2443-57. doi: 10.1002/art.27515.

16.

B-cell biology and related therapies in systemic lupus erythematosus.

Ahmed S, Anolik JH.

Rheum Dis Clin North Am. 2010 Feb;36(1):109-30, viii-ix. doi: 10.1016/j.rdc.2009.12.002.

PMID:
20202594
17.

B cells in the pathogenesis and treatment of rheumatoid arthritis.

Marston B, Palanichamy A, Anolik JH.

Curr Opin Rheumatol. 2010 May;22(3):307-15. doi: 10.1097/BOR.0b013e3283369cb8. Review.

18.

Novel human transitional B cell populations revealed by B cell depletion therapy.

Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH.

J Immunol. 2009 May 15;182(10):5982-93. doi: 10.4049/jimmunol.0801859.

19.

Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.

Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I.

Immunol Res. 2009 Dec;45(2-3):144-58. doi: 10.1007/s12026-009-8096-7. Epub 2009 Apr 7. Review.

20.

Two negative randomized controlled trials in lupus: now what?

Coca A, Anolik JH.

F1000 Med Rep. 2009 May 8;1. pii: 28. doi: 10.3410/M1-28.

Supplemental Content

Loading ...
Support Center